Circular Polyribonucleotide Dosing Regimens for Sustained Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for maintaining protein expression in mammals using circular polyribonucleotides are inefficient, as they often result in transient expression due to rapid degradation or immune recognition, leading to short-lived protein levels.
Innovation Solution
A method involving multiple dosing regimens of circular polyribonucleotides, including redosing and staggered dosing, is employed to maintain protein expression by administering compositions over extended periods, utilizing exogenous, synthetic circular polyribonucleotides that lack poly-A sequences and replication elements, to sustain protein levels and avoid immune detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a single dose of circular polyribonucleotide is administered, then initial protein expression is achieved, but protein expression levels decline rapidly due to degradation and immune recognition
Solution Approach 1:
The patent implements periodic dosing regimens where circular polyribonucleotide compositions are administered at scheduled intervals (e.g., every 1-4 weeks) to maintain therapeutic protein expression levels. This periodic administration counteracts the natural decline in expression caused by degradation and immune recognition, ensuring continuous therapeutic effect without requiring constant presence of the nucleotide.
Solution Approach 2:
The patent employs preliminary protective measures by administering immunosuppressive agents or modifying the circular polyribonucleotide structure beforehand to reduce immune recognition. This preliminary action prevents rapid clearance and degradation that would otherwise occur after administration, thereby extending the duration of protein expression.
2Duration of action of moving object
If multiple dosing regimens are implemented to maintain protein expression, then duration of action is extended, but treatment complexity and frequency of administration increase
Solution Approach 1:
The patent establishes standardized periodic dosing schedules (e.g., weekly, bi-weekly, or monthly administrations) that provide predictable maintenance of therapeutic levels. These regular intervals simplify treatment planning and patient compliance compared to irregular or response-based dosing, reducing the perceived complexity despite multiple administrations.
Solution Approach 2:
The patent optimizes dosing parameters such as interval timing, administered dose size, and formulation characteristics to achieve the longest possible duration of action with the fewest administrations. By carefully tuning these parameters, the treatment balances extended duration with minimized dosing frequency and complexity.
Data Source
AI summary
This invention relates generally to methods of dosing pharmaceutical compositions and preparations of circular polyribonucleotides thereof.